Aura Biosciences, Inc. 8-K

What Happened
Aura Biosciences, Inc. (AURA) announced an underwritten public offering that closed May 5, 2026, raising approximately $280.8 million in net proceeds. The offering consisted of 39,591,000 firm shares of common stock and pre-funded warrants to purchase up to 3,800,000 shares, at $6.00 per share (pre-funded warrants at $5.99999). The underwriters’ 30‑day option to purchase an additional 6,508,650 shares was exercised in full on May 4, 2026. The company also intends to use about $39.0 million of the net proceeds to repurchase 6,922,870 shares from Matrix Capital Management Master Fund, LP at $5.64 per share.

Key Details

• Offering closed: May 5, 2026; underwriters’ option exercised in full on May 4, 2026 (additional 6,508,650 shares).
• Price and instruments: $6.00 per common share; pre-funded warrants sold at $5.99999 with $0.00001 exercise price; warrants exercisable immediately.
• Net proceeds and use: ~ $280.8M net proceeds; ~$241.8M expected for clinical programs (including early choroidal melanoma) and registration-enabling activities for bel‑sar; ~$39.0M for the Matrix share repurchase.
• Cash runway: Company believes cash (including proceeds) funds operations into the second half of 2028.

Why It Matters
This financing materially increases Aura’s cash position and funds its clinical and regulatory programs, reducing near-term financing risk. The planned repurchase of Matrix-held shares is a significant insider share buyback funded from the offering proceeds and may affect share count and ownership. Investors should note the dilution from the issued shares and pre-funded warrants and the company’s stated allocation of proceeds toward advancing its oncology pipeline and corporate needs.